Lupin Peer Comparison

Lupin Ltd. stands out among its peers with strong growth metrics, solid profitability, and attractive valuation ratios. The company shows a robust revenue growth of over 20% YoY, a high ROE of over 21%, and a low debt-equity ratio, positioning it as a leader in the pharmaceuticals sector. In comparison, some peers appear overvalued while others show signs of financial stress.

• • Lupin Ltd. has the highest revenue growth (YoY) at 20.24%.
• • Dr. Reddy's Laboratories leads in profitability metrics with the highest ROE (21.76%) and ROCE (26.86%).
• • Cipla Ltd. offers attractive valuation with a PE ratio of 23.73, while Sun Pharmaceutical appears overvalued with a PE of 87.59.
• • Divi's Laboratories Ltd. displays high profit margins but struggles with revenue growth, making it a financially weak pick.

• • Lupin Ltd.: Highest revenue growth YoY at 20.24% and solid EPS growth of 71.84.
• • Dr. Reddy's Laboratories Ltd.: Leads in ROE (21.76%) and ROCE (26.86%), indicating strong profitability.
• • Cipla Ltd.: Offers attractive valuation metrics with a PE of 23.73 and solid growth.